ACS Releases New Clinical Guidance Document for Elective Surgical Case Triage during COVID-19

The American College of Surgeons (ACS) continues to provide guidance for surgeons to curtail recommendations for elective surgical procedures to preserve the necessary resources for care of critically ill patients during the COVID-19 pandemic.

To assist in surgical decision-making in curtailing cases, ACS has released “COVID-19: Elective Case Triage Guidelines for Surgical Care,” a new surgical triage document that was developed following expert review in several specialties and provides trusted information from the most current best evidence available in the following areas:

These triage recommendations should be used in conjunction with a joint statement ACS has developed with the American Society of Anesthesiologists and the Association of periOperative Registered Nurses recommending medical centers develop a Surgical Review Committee to act as an administrative body to provide defined, transparent, and responsive oversight for triaging surgical cases during the COVID-19 pandemic.

The ACS, ASA, and AORN recommend decisions of the Surgical Review Committee regarding surgical cases be made on a daily basis, no later than the day before an operation, and should include a multidisciplinary leadership team representing surgery, anesthesiology, and nursing.

“These triage guidelines and joint recommendations are being issued as we appear to be entering a new phase of the COVID-19 pandemic with more hospitals facing a potential push beyond their resources to care for critically ill patients. ACS will continue to monitor the landscape for surgical care but we feel this guidance document provides a good foundation for surgeons to begin enacting these triage recommendations today to help them make the best decisions possible for their patients during COVID-19,” said ACS Executive Director David B. Hoyt, MD, FACS.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”